Absorption of insulin from pluronic F-127 gels following subcutaneous administration in rats.
The main objective of this work was to evaluate the use of Pluronic (PF127) gels, polylactic-co-glycolic acid (PLGA) nanoparticles and their combination for parenteral delivery of peptides and proteins having short half-lives using insulin as a model drug. The in vitro insulin release profiles of various PF127 formulations were evaluated at 37 degrees C using a membraneless in vitro model. In vivo evaluation of the serum glucose and insulin levels was performed following subcutaneous administration of various insulin formulations in normal rats. The in vitro results demonstrated that the higher the concentration of PF127 in the gel, the slower the release of insulin from the matrices, independent of the vehicle used. The acute hypoglycemic peak resulting from administration of an insulin solution between 0.5 and 2.0 h after administration (peak at 1 h) is replaced after administration of insulin-PLGA nanoparticles by an almost constant hypoglycemic effect with a slower recovery of the serum glucose levels at about 2 h after administration. By loading insulin into PF127 gels, a slower and more prolonged hypoglycemic effect of insulin was obtained in inverse proportion to the polymer concentration. PF127 gel formulations containing insulin-PLGA nanoparticles had the most long-lasting hypoglycemic effects of all formulations. From the current in vitro and in vivo study, we concluded that PF127 gel formulations containing either drug or drug-nanoparticles could be useful for the preparation of a controlled delivery system for peptides and proteins having short half-lives.
Barichello
J M
JM
Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Hoshi University, Ebara-2-4-41, Shinagawa-Ku, Tokyo 142-8501, Japan.
Morishita
M
M
Takayama
K
K
Nagai
T
T
D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D005079:Excipients; D005782:Gels; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000494:pharmacology; D007279:Injections, Subcutaneous; D007328:Insulin / Q000008:administration & dosage* / Q000494:pharmacology; D019344:Lactic Acid; D008297:Male; D008863:Microspheres; D020442:Poloxamer; D011100:Polyglycolic Acid; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011108:Polymers; D051381:Rats; D017208:Rats, Wistar; D012869:Skin Absorption; D012996:Solutions
D001786:Blood Glucose; D005079:Excipients; D005782:Gels; D007004:Hypoglycemic Agents; D007328:Insulin; D011108:Polymers; D012996:Solutions; D020442:Poloxamer; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid